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BY-NC-ND license (http://creativecomAbstract Background: Providencia stuartii survives well in natural environment and often
causes opportunistic infection in residents of long-term care facilities (LTCFs). Clinical isolates
of P. stuartii are usually resistant to multiple antibiotics. The bacterium is also naturally resis-
tant to colistin and tigecycline. Treatment of infections caused by carbapenem-resistant P.
stuartii is challenging.
Methods: During a 15-month period in 2013e2014, four isolates (P1, P2, and P3B/P3U) of P.
stuartii showing intermediate resistance to imipenem were identified at a regional hospital
in southern Taiwan. They were identified from three patients (P1eP3) transferred from the
same LTCF for the treatment of the infection. Pulsed-field gel electrophoresis was used to ge-
notype the isolates. Resistance genes/plasmids and outer membrane proteins were investi-
gated by polymerase chain reaction and sequence analysis.
Results: Isolates P1 and P3B/P3U demonstrated similar pulsotypes. All isolates were found to
have resistance genes (blaCMY-2, qnrD1, aac(6
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dx.doi.org/10.1016/j.jmii.2016.07.00plasmids of different sizes. A single point mutation was identified in the chromosomal gyrA
(Ser83Ile) and parC (Ser84Ile) genes of all isolates. Various point mutations and insertion/dele-
tion changes were found in their major outer membrane protein gene ompPst1.
Conclusions: Isolates of similar pulsotypes could appear after 15 months and caused urosepsis
in another resident of the same LTCF. The bacterium may have persisted in the environment
and caused opportunistic infection. As LTCF residents are usually vulnerable to infections, sur-
veillance of multidrug-resistant organisms and infection control intervention that have been
established in acute-care hospitals to control infections by resistant organisms are apparently
as essential in LTCFs.
Copyright ª 2016, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
With the extension of human life, growing demand for long-
term care facilities (LTCFs) appears inevitable. Residents of
LTCFs are usually with advanced ages and are associated
with a variety of clinical disabilities, chronic diseases, and
compromised immune status, making them vulnerable to a
variety of infections.1 The generally close living proximity,
frequent contact between nursing staff and residents, and
less optimized infection control measures may facilitate
the spread of microbial organisms and increase infection
burden.2 These conditions may lead to the necessity for
frequent prescription of antimicrobial agents. However,
diagnosis of infection among these elderly residents is often
difficult, resulting in the increase of inappropriate antimi-
crobial use and the development of multidrug-resistant
organisms (MDROs).1,3 The frequent visits or transfers be-
tween LTCFs and acute-care settings may further worsen
the problem in terms of infection acquisition or resistance
development.4
Providencia stuartii, a Gram-negative bacterium
belonging to the family of Enterobacteriaceae, can survive
well in natural environment, including water and soil.5 The
bacterium often causes opportunistic infection in hospi-
talized patients or LTCF residents. Particularly among those
with indwelling urinary catheters, P. stuartii could cause
bacteriuria and further develop into bacteremia.6 Any flaw
in the infection control measures may result in cross
infection among the patients or even lead to infection
outbreaks.7e11
Clinical isolates of P. stuartii are often resistant to
multiple antibiotics. Despite the natural presence of chro-
mosomal AmpC genes, P. stuartii could also acquire various
exogenous resistance genes and develop the resistance to
multiple antimicrobial agents, including
carbapenems.7e10,12e14 Clinically, colistin and tigecycline
are usually considered for infections caused by
carbapenem-resistant Enterobacteriaceae (CRE). However,
P. stuartii also possesses natural resistance to these two
antibiotics.15,16 In other words, when treating infections
caused by carbapenem-resistant P. stuartii, clinicians may
fall in a dilemma that no appropriate antibiotic is available.
At a regional hospital in southern Taiwan, two isolates of
P. stuartii that showed intermediate resistance to imipe-
nem were identified from blood specimens of two patientsao Y-C, et al., Laboratory investig
at a long-term care facility, Jo
4in May and June 2014, respectively. The two patients were
referred from the same LTCF for the treatment of the
infection. As the situation was relatively rare, the occur-
rence of an outbreak in the LTCF was highly suspected.
Retrospective analysis revealed that in March 2013, another
imipenem-intermediately resistant P. stuartii isolate had
been identified from another patient also from the LTCF.
The present study was therefore performed aiming to
elucidate the relationship of these isolates and the under-
lying resistance mechanisms.Materials and methods
Bacterial isolates and patients
Four isolates of P. stuartii showing intermediate resistance
to imipenem were studied. The first one was identified in
March 2013 from the abscess specimen of the first patient
(P1). The second one was isolated from the blood specimen
of another patient (P2) in May 2014. In June 2014, two more
isolates were identified from the blood (P3B) and urine
(P3U) specimens of a third patient (P3). The three patients
were from the same LTCF before being admitted to this
hospital. Therefore, medical charts were reviewed and the
isolates were submitted for the following laboratory ex-
aminations. For comparison, another two imipenem-
intermediately resistant P. stuartii isolates were included
as controls in genotyping analysis. They were identified
from patients of other sources during the study period.Antimicrobial susceptibility testing
Minimum inhibitory concentrations of the isolates were
examined by the BD PHOENIX automated microbiology
system (Becton Dickinson Diagnostic Systems, Sparks, MD,
USA). Antimicrobial agents tested were b-lactams (cefe-
pime, cefotaxime, ceftazidime, ceftriaxone, cefuroxime,
imipenem, meropenem, piperacillin, and piperacillin/
tazobactam), aminoglycoside (amikacin), fluoroquinolone
(levofloxacin), phenicol (chloramphenicol), and
trimethoprim-sulfamethoxazole. All results were inter-
preted according to the criteria suggested by the Clinical
and Laboratory Standards Institute.17ation of a suspected outbreak caused by Providencia stuartii with
urnal of Microbiology, Immunology and Infection (2016), http://
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To reveal the genetic relationship of the isolates, pulsed-
field gel electrophoresis was performed using a method
described previously.8 Briefly, bacterial suspensions were
embedded in plugs and treated with SmaI. The resulting
macrorestricted DNA fragments were then subjected to
electrophoresis using a CHEF Mapper XA System (Bio-Rad
Laboratories, Hercules, CA, USA). An autoalgorithm mode
was selected with the running molecular weights ranging
from 20 kb to 300 kb. The criteria proposed by Tenover et
al.18 were used for the interpretation of the resulting pat-
terns. Isolates showing identical banding patterns were
designated as the same pulsotypes. Those which varied by
one to three bands were defined as subtypes of the same
pulsotypes. Isolates which differed by four or more bands
were considered as different pulsotypes.
Mechanisms of antimicrobial resistance
The presence of genes encoding for extended-spectrum b-
lactamases, AmpC b-lactamases, and carbapenemases was
examined by polymerase chain reactions (PCRs) followed by
sequence analysis.19,20 For fluoroquinolone resistance,
PCR/sequencing was also used to detect the mutations
present in the quinolone resistance-determining regions
among the chromosomal gyrA, gyrB, parC, and parE genes
as well as the existence of plasmid-mediated fluo-
roquinolone resistance genes, such as aac(60)-Ib, qnr, qep,
and oqx.21 The two major outer membrane proteins,
ompPst1 and ompPst2, of P. stuartii were also analyzed by
PCR/sequencing to reveal the presence of mutations.22
Plasmid analysis followed by Southern hybridization was
used to examine the location of various resistance genes.19
Conjugation experiments were performed by using Escher-
ichia coli J53 as the recipient to reveal whether the resis-
tance plasmids are self-transferrable.19 Replicon typing was
performed to delineate the genetic correlation of the
resistance plasmids.19
Results
Clinical characteristics of the three patients are listed in
Table 1. They were all male patients and aged over 60 years
old. Various underlying diseases had led to a bedridden orTable 1 Clinical characteristics of the patients.
Patient Age
(y)
Admission
(y/mo)
Admission
diagnosis
Underlying
disease
Specim
Date
P1 67 2013/3 Bed sore Diabetes,
stroke
4 Days after
admission
P2 81 2014/5 Urosepsis Brain
hemorrhage
On admission
P3 63 2014/6 Urosepsis Alcoholic
hepatitis
On admission
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P1 was admitted to this hospital 14 months earlier than P2,
whereas P2 was hospitalized 37 days earlier than P3. The
specimens of P2 and P3 were obtained on the respective
admission dates, whereas P1 was obtained 4 days after hos-
pitalization. Various antibiotics had been used among these
patients in the 3 months prior to the hospitalization, but only
patient P3 had used imipenem and levofloxacin. Several last-
line antibiotics were used to treat the P. stuartii infection. All
patients recovered and were discharged.
Results of the laboratory investigation are shown in Table
2. Among the five groups of antibiotics tested, only amino-
glycoside (amikacin) remained susceptible. For b-lactam
antibiotics, the isolateswere susceptible only tomeropenem,
cefepime (2 in the susceptible-dose dependent category),
and piperacillin-tazobactam (nZ 3). All isolates showed in-
termediate resistance to imipenem (minimum inhibitory
concentration, 2 mg/mL). Pulsed-field gel electrophoresis
analysis revealed that isolates P1 and P3B/P3U were closely
related. The other isolates, P2 and the two control isolates
demonstrated different pulsotypes (Figure 1).
Various resistance genes were identified among the iso-
lates (Table 2). Several genes, such as blaCMY-2, qnrD1, and
aac(60)-Ib-cr, were present on plasmids and were associated
with the resistance to the third-generation cephalosporins
and fluoroquinolones. The plasmids carrying these resis-
tance genes were of different sizes, but all belonged to the
IncA/C family. Despite several trials, we were not able to
demonstrate the self-transferability of the plasmids. None
of the known carbapenemase genes was found.
Various point mutations and insertion/deletion changes
were found in one of the major outer membrane protein
genes, ompPst1 (data not shown). Amino acid sequences of
the other outer membrane protein gene, ompPst2, were
identical with those of the reference strain P. stuartii ATCC
29914.
A single point mutation was found in the chromosomal
gyrA (codon 83, AGC to ATC) and parC (codon 84, AGT to ATT)
genes, both leading to the amino acid change from serine to
isoleucine (Table 2). The changes were also related to the
observed fluoroquinolone resistance among the isolates.
Discussion
Despite the close temporal and spatial correlation, geno-
typing analysis revealed that isolates from patients P2 anden Antibiotics in
the prior 3 mo
Antibiotics for
the infection
Outcome
Type
Abscess Ampicillin-
sulbactam
Vancomycin,
ceftazidime,
metronidazole,
tigecycline
Recovered and
discharged
Blood Ceftriaxone,
ceftazidime
Doripenem Recovered and
discharged
Blood/
urine
Imipenem,
vancomycin,
levofloxacin
Doripenem Recovered and
discharged
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Figure 1. Pulsed-field gel electrophoresis of the four isolates
of Providencia stuartii (P1, P2, P3B, and P3U) studied and two
control isolates (C1 and C2). M, lambda DNA concatemer
standard.
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dx.doi.org/10.1016/j.jmii.2016.07.004P3 were not genetically related. However, another isolate
from patient P1, although identified more than 1 year ago,
showed an unexpectedly similar pulsed-field gel electro-
phoresis pattern to those from patient P3. Even though we
were not able to conduct environmental surveillance in the
LTCF, it is highly suspected that the bacterium may have
inhabited in the LTCF and caused opportunistic infections.
Previous reports indicated that P. stuartii could reside in a
hospital environment, such as hand-washing sinks8 and
tracheal aspirators/probes/tubes,11 and cause outbreaks of
nosocomial infections. In fact, due to the characteristics of
LTCF residents, as well as the strategy of nursing care in
such institutions, a wide spectrum of MDROs has been found
to colonize the environment of LTCFs, causing cross-
transmission or outbreaks of infections with high mortal-
ity.23e25 In Taiwan, similar situations also have been re-
ported for other MDROs, but never in P. stuartii.26,27
Urinary tract infection could be associated with as high
as more than 40% of the LTCF residents.28 Asymptomatic
bacteriuria could be even higher in almost 60% of such
populations, and 16.2% of the cases could be associated
with P. stuartii.29 The present study further demonstrated
that genetically closely-related P. stuartii could cause
infection in different residents even in more than 1 year
apart. Actually, multidrug-resistant P. stuartii has been
reported to cause cross-transmission and infection for more
than 4 years in one single hospital.10 Another report also
demonstrated a 2-year outbreak in a burn unit caused by
multidrug-resistant P. stuartii.9 In the present study, it
remains unknown whether P. stuartii caused asymptomatication of a suspected outbreak caused by Providencia stuartii with
urnal of Microbiology, Immunology and Infection (2016), http://
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+ MODELbacteriuria in other residents or infections that were
treated in other hospitals. However, as LTCF residents are
usually vulnerable to infections, surveillance of MDROs and
infection control interventions that have been established
in acute-care hospitals to control infections by resistant
organisms are apparently as essential in LTCFs.30,31 In fact,
the Association for Professionals in Infection Control and
Epidemiology and the Society for Healthcare Epidemiology
of America have established guidelines for the infection
prevention and control in LTCFs.32 Governments in other
countries, such as the United Kingdom, also have provided
sources of information on this regard.33 However, there are
still some countries, including Taiwan, that have not yet
established such a system. It is apparently an important
requisition that special care has to be implemented in
LTCFs to prevent the formation of infection reservoirs and
spread of MDROs among LTCFs.
P. stuartii is known to possess chromosomal AmpC genes
and is therefore naturally resistant to aminopenicillins and
narrow-spectrum cephalosporins.34 Nevertheless, the four
isolates studied herein still acquired another plasmid-
mediated AmpC gene, blaCMY-2, and thereby broadened
the resistance spectrum to include the third-generation
cephalosporins.34 The situation is similar to some recent
reports published elsewhere.8,9 Furthermore, plasmid-
mediated fluoroquinolone resistance genes, qnrD1 and
aac(60)-Ib-cr, were identified, and combined with the point
mutations in the chromosomal gyrA and parC genes, have
resulted in the observed high-level resistance to fluo-
roquinolones in our isolates. Similar problems have only
recently been reported.7,12 In fact, qnrD1 and aac(60)-Ib-cr
were only sporadically found in previous reports from
Taiwan.21,35 The coexistence of these fluoroquinolone
resistance genes and the AmpC gene, blaCMY-2, on the same
plasmids, as found among the study isolates herein, may
represent another potential mechanism for the dissemina-
tion of resistance genes and thus the increase of MDROs in
LTCFs.
Clinically, empirical therapy by carbapenems is sug-
gested for life-threatening infections or those associated
with multidrug-resistant Gram-negative organisms,
including P. stuartii.36 Patients P2 and P3 studied herein
were indeed successfully cured with doripenem. However,
the four isolates studied all expressed low-level resistance
to imipenem. Some amino acid changes were revealed in
the major outer membrane protein OmpPst1. Previous re-
ports from Taiwan indicated that the major mechanism for
the development of CRE was the production of extended-
spectrum b-lactamase- or AmpC-type enzymes plus muta-
tions in the outer membrane proteins.20,37,38 Therefore, if
the factors associated with the currently observed muta-
tional changes persisted, the outer membrane proteins of
these imipenem-intermediately resistant P. stuartii may
continue to mutate, eventually leading to full resistance to
all carbapenems. Since P. stuartii is naturally resistant to
colistin and tigecycline,15,16 the two antimicrobial agents
frequently used for CRE infection, treatment for P. stuartii
showing full resistance to carbapenems will become a big
challenge. Furthermore, compared to meropenem, imipe-
nem was shown to have a lower level of permeation through
the major outer membrane protein OmpPst1 in P. stuartii.39
The observation was well correlated with the lowerPlease cite this article in press as: Mao Y-C, et al., Laboratory investig
intermediate resistance to imipenem at a long-term care facility, Jo
dx.doi.org/10.1016/j.jmii.2016.07.004antibiotic susceptibility of the bacterium to imipenem than
to meropenem.39 The actual underlying mechanism for this
relative difference in susceptibilities to the two carbape-
nems remains to be identified. However, the use of imipe-
nem is likely to provide more selection pressure and hence
induce more mutational changes in OmpPst1, leading to
higher resistance levels to imipenem, or even to other
carbapenems. Therefore, even if antimicrobial suscepti-
bility testing does not demonstrate a resistance result,
imipenem is apparently not appropriate for the treatment
of P. stuartii infection.
In conclusion, the present study demonstrated the pos-
sibility for a long-term habitation of multidrug-resistant P.
stuartii in one LTCF. Similar situations may be found in
other multidrug-resistant microbial pathogens. LTCFs
appear to be a convenient reservoir for antimicrobial
resistant organisms. Surveillance of MDROs and infection
control intervention are both required for LTCFs to reduce
the infection loads associated with multidrug-resistant
bacteria.40
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